Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Background Adjuvant abemaciclib combined with endocrine therapy (ET) previously
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …

Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in
breast cancer, has limited value for treatment decisions due to questionable analytical …

PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
recurrence or have distant recurrence with currently available standard therapies. However …

PURPOSE About one third of patients with hormone receptor–positive, human epidermal
growth factor receptor 2–negative breast cancer who have residual invasive disease after …

The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for
hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative …

Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …

The treatment of breast cancer has improved dramatically over the past century, from a
strictly surgical approach to a coordinated one, including local and systemic therapies …

Purpose: neoMONARCH assessed the biological effects of abemaciclib in combination with
anastrozole in the neoadjuvant setting. Patients and Methods: Postmenopausal women with …